INTRODUCTION

Hypertension is the major risk factor for cardiovascular disease. The WHO declared it ‘the number one killer’ in The World Health Report of year 2001. It is important to note that hypertensive patients have four times greater chances for stroke and Two times greater chances myocardial infarction (a heart attack) than those who have normal blood pressure. The chances of complications increase with rise in level of blood pressure. It is reported that a 5mmHg drop of blood pressure, reduces risk of stroke by 14%, coronary heart disease by 9% and overall chances of mortality by 7%.

Hypertension is the most common cardiovascular disease in Pakistan as well. The National Heath Survey of Pakistan reported incidence of high
blood pressure in 18% of adults over 18 year of age and 33% of adults over 45 years. There are different reports showing different figures of rates of prevalence, awareness, treatment and control. The experts developed guidelines for safe and better management of hypertension for the health providers and general public on the basis of clinically and scientifically sound and validated evidences. Juxtaposing, different guidelines (Table-I) for initial or Stage I therapy for hypertension without compelling indications use of Thiazide Diuretics, Angiotensin Converting Enzyme Inhibitors (ACEIs) or Calcium Channel Blockers (CCB) are widely recommended. The JNCVII Guidelines strongly recommends thiazide for “most of the patients”. Pakistan Hypertension Leagues’ guideline has more or less adopted NICE (UK) recommendations. NICE recommends ACEIs to patients younger than 55 years whereas CCB and diuretics to patients 55 years or blacks. Beta Blockers (BBs), once considered as key medication, are not recommended for initial or Stage I therapy for hypertension except in compelling conditions. Combinations of more than one drug are also encouraged to achieve therapeutic goal. Use of generic drugs is recommended to reduce prescription cost.

Key issues, globally, are lack of adherence to therapeutic guidelines for hypertensive therapy by the doctors, and lack of patients’ awareness of disease as well as compliance to their doctors’ recommendations. In Pakistan, the situation is not different; there are reports of very low awareness of disease and observance to doctors’ advice in patients and wide deviations to the therapeutic guidelines available for health providers in Pakistan. Jafar et al. (2005) asked for special efforts to encourage doctors (particularly general practitioners) for prescribing cost effective regimen. In another study by Hameed et al. (2004) reported misconceptions in understanding and treatment of hypertension among a group of doctors. He found that 50% of the general practitioners (GPs) attending a Continuous Medical Education (CME) workshop on hypertension could not define hypertension, whereas 75% of them believed that anxiolytics were the first line therapy for hypertension. The major hurdles in the management of hypertension that

| S. No. | Excerpts from the Guidelines | Evidence-based clinically ascertained guidelines for the management of hypertension |
|-------|----------------------------|-----------------------------------------------------------------|
| 1     | Initial Drug Choice:       | PHL<sup>13</sup> JNC VII<sup>14</sup> WHO/ISH<sup>15</sup> NICE<sup>16</sup> South Africa<sup>17</sup> |
| 2     | Cost reducing measures:    | “Diuretics, being very economic drugs may be used as a first line therapy in countries like Pakistan...” |
| 3     | Use of BBs for initial therapy: | More recently the BBs are deemphasized due to their diabetogenic potentials. |

**Table-I: Summary of National and International Guidelines for the Management of Hypertension.**

Abbreviations: PHL = Pakistan Hypertension League. JNC = Joint National Commission on Hypertension, National Institute of Health USA. WHO = World Health Organization. ISH = International Society of Hypertension. NICE = National Institute Health, UK. ACEIs = Angiotensin Converting Enzyme Inhibitors. CCBs = Calcium Channel Blockers. BBs = Beta Blockers.
emerged from the reports were financial constraints, non-compliance to treatment regime and lack of follow-up with physicians.4

Impact of hypertension on healthcare cost is huge. In USA, it cost US$ 73.4 billion in the year 2009. The financial requirements for antihypertensive therapy in Brazil was US$ 9.6 billion in 2012 with 24% increase during the year 2010 -2012.5,6 Search and efforts for reducing cost of antihypertensive therapy has been intensive worldwide i.e. Brazil, Caribbean countries, Malaysia, Poland, and USA.7,10 It was found by the American Heart Association (ASA) that the medication cost was 45% of total direct cost of therapy.17 To reduce cost of therapy, Fischer (2004) after studying more than two million prescriptions for antihypertensive medications in 2001, costing US$ 48.5 million per annum (363 dollars per patient), identified that 40% of prescriptions of medication for which an alternative evidence-based expert recommended cost-effective regimen was available. He calculated that this change would have saved the costs to payers in 2001 by US$11.6 million (nearly a quarter of program spending on antihypertensive medications). Moreover, he suggested replacement was evidence-based for clinical appropriateness on global basis. The largest potential saving was due to replacement of calcium channel blockers.12

Our objective was to find out drug usage trends in Stage I Hypertensive Patients without any compelling indications in Karachi, deviations of current practices from evidence based antihypertensive therapeutic guidelines and looking for cost minimization opportunities.

METHODS

Three pronged approach was used. Two randomized stratified surveys were conducted in health providers (doctors) and health receivers (general population including patients) using pretested questionnaires. Sample size for doctors was 100 (58 general practitioners and 42 doctors working in hospital OPDs) and for general population was 400 (200 males and 200 females) from different socio-economic areas of Karachi. Specialists and consultants were excluded from the study. Data of prescriptions, prescription trends, and drug prices were obtained from authentic sources. Statistical analysis was conducted on Statistical Package for Social Science (SPSS). Financial impact was also analyzed. The study was conducted during June 2012 to August 2012 and it was approved by Ethics Review Committee of Liaquat National Hospital Karachi.

RESULTS

The present study aims to determine the drug usage trends in Stage I hypertension without any compelling indications in Karachi, identifies deviations of current prescribing practice from the evidence based antihypertensive therapeutic guidelines, and looks for therapeutic cost minimization opportunities.

The Table-II tabulates hypertensive patients’ feedback (N=400) on their first prescribed hypertensive drug. It was found that majority of them were prescribed Beta Blockers (33%), followed by Angiotensin Converting Enzyme (ACE) (18%), and

| S. No. | Antihypertensive Class | Score of responses | Main drugs used (name & score) |
|-------|------------------------|--------------------|--------------------------------|
| 1     | Beta Blockers (BB)     | 27                 | Atenolol # 19 (68% Brand Leader) |
|       |                        |                    | Propranolol # 8                  |
| 2     | Angiotensin Converting Enzyme Inhibitors (ACEIs) | 15                 | Ramipril # 6                     |
|       |                        |                    | Enalapril # 6 (100% Brand Leader) |
| 3     | Calcium Channel Blockers (CCB) | 11               | Amlodipine # 9                   |
|       |                        |                    | Nimodipine # 1                   |
|       |                        |                    | Verapamil # 1                    |
| 4     | Angiotensin Receptor Blockers (ARBs) | 7                  | Losartan # 7 (14% on Brand Leader) |
| 5     | Non-Thiazide Diuretics | 7                  | Furosemide # 6 (16% Brand Leader) |
| 6     | Antihypertensive Combinations | 2               | HCTZ + ACEI # 1                  |
| 7     | Thiazide Diuretics (HCTZ) | none              | No prescription                  |
| 8     | Could not recall drug’s name | 14               | None                            |

Our objective was to find out drug usage trends in Stage I Hypertensive Patients without any compelling indications in Karachi, deviations of current practices from evidence based antihypertensive therapeutic guidelines and looking for cost minimization opportunities.
Calcium Channel Blockers (13%). Diuretics were prescribed to 8% of them. The diuretics included furosemide and amiloride with furosemide. Nobody got thiazide diuretics. Usage of combination drugs was found in 3% of the respondents. It was also found that majority of them got high priced brand leader (original patent). 17% patients could not recall names of their antihypertensive drugs.

Table-III shows doctors response to two queries. When the doctors (N=100) were asked about their choice of first line (Step I) antihypertensive agents in patients without compelling indications, they preferred Beta Blockers (34%) and ACEIs (34%) over other antihypertensive agents e.g. diuretics (17%), Calcium Channel Blockers (4%), and others (11%).

Responding to query asked for their perception of the most cost-effective drug, 29 % of the doctors opined Beta Blockers, followed by Angiotensin Converting Enzymes inhibitors (18%) and diuretics (12%). There was no significant difference in the initial choice of drugs for patients of Stage I hypertension with no compelling indications and perception about cost effectiveness in general practitioners and doctors working in the hospitals.

Table-IV gives picture of non-pharmacologic interventions in hypertension mentioned by the patients. 84% of the patients acknowledged doctors’ advice for physical exercise whereas 95% remembered doctors’ recommendations for changing dietary habits. Most of the patients recalled medical advice for 30-minute brisk walk for five days a week and salt, fat-rich and high sugar intake reduction.

Table-V gives comparison of annual cost of therapy to a patient. It shows that hydrochlorothiazide (HCTZ) from a national company is the most cost-effective antihypertensive costing only Rs. 367 yearly per patient. When Branded Market Leaders of ACEIs, CCBs, BBs and ARBs annually cost Rs. 3,041; Rs. 6,532; Rs.3,652; and Rs. 28,278 respectively.

### Table-III: Doctors' first line antihypertensive therapeutic agents and perception of cost effectiveness (Primary Data) [N=100].

| S. No | Classes of Antihypertensive Drugs | Doctors' choice of drug for initial antihypertensive therapy and perception of cost effectiveness |
|-------|-----------------------------------|--------------------------------------------------------------------------------------------------|
|       | Q: Which is the drug you would like to use as the first line hypertensive in patients without compelling indications? | Q: Which is the most cost effective antihypertensive drug in your opinion? |
|       | General Practitioners | Hospital Doctors | Overall Total | General Practitioners | Hospital Doctors | Overall Total |
|-------|-----------------------|------------------|--------------|-----------------------|------------------|--------------|
| 1     | Diuretics             | 9                | 16%          | 8                     | 19%              | 17%          | 5            | 9%            | 7               | 17%              | 12%            |
| 2     | Angiotensin Converting Enzymes Inhibitors (ACEIs) | 20               | 34%          | 14                    | 33%              | 34%          | 9            | 16%          | 9               | 21%              | 18%            |
| 3     | Calcium Channel Blockers (CCBs) | 3                | 5%           | 1                     | 2%               | 4%           | 3            | 5%           | 4               | 10%              | 7%             |
| 4     | Angiotensin Receptor Blockers (ARBs) | -                | -            | -                     | -                | -            | 7            | 7%           | 7               | 7%               |
| 5     | Beta Blockers (BBs)    | 19               | 33%          | 15                    | 36%              | 34%          | 16           | 28%          | 13              | 31%              | 29%            |
| 6     | Combinations           | -                | -            | -                     | -                | -            | 7            | 12%          | 0               | 7                | 7%             |
| 7     | Not mentioned          | 7                | 12%          | 4                     | 10%              | 11%          | 16           | 28%          | 7               | 17%              | 22%            |
|       | Total                 | 58               | 42%          | 100                   | 58               | 42%          | 100                      |

### Table-IV: Non-pharmacologic intervention for controlling high blood pressure (Patients' Feedback)

| S. No | Survey Questions                                                                 | Subject’s Feedback (N=83) | Additional Feedback related to Survey Questions. |
|-------|----------------------------------------------------------------------------------|---------------------------|--------------------------------------------------|
|       |                                                                                   | Yes | No | No Response |                                                                 |
| 1     | Has your doctor advised you for physical exercise as a measure to control hypertension? | 70  | 44%| 12 | 14% | 2% | 30-minute brisk walk five days a week |
| 2     | Has your doctor or any other health professional ever advised you to change your dietary habits for better control of hypertension? | 79  | 95%| 3  | 4%  | 1% | • Reduce Salt intake  
• Avoid fatty high sugar containing food. |
The Branded Market leaders are 8 to 77 times costlier than above mentioned HCTZ. Even the generic drugs of chemical moieties’ average prices are 5 to 19 times whereas the lowest priced generics are 2 to 8 times more expensive than HCTZ. Price difference between the generics and the branded market leaders ranges from 1.2 to 4 times more expensive. Branded market leaders are 4 to 9 times more expensive than their lowest priced generic drugs.

**DISCUSSION**

Table-I contains relevant points from one national and four international evidence-based therapeutic guidelines for the management and treatment of hypertension. All these guidelines recommend use of thiazide diuretics as the drug of first choice in patients of Stage 1 hypertension without any compelling indications. JNC VII (even JNC VIII) recommends initial therapy with diuretics in such cases. Both the UK’s National Institute of Clinical Excellence (NICE) and Pakistan Hypertension League (PHL) recommend ACEIs for non-black and those younger than 55 years and CCBs and diuretics for black and those older than 55 years. Diuretics are recommended because of safety, cardiovascular protection, and economy. Besides diuretics, ACEIs and CCBs are also recommended. Another important but worth considering point is de-emphasize on BBs because of their diabetogenic effects. All these guidelines underscore use of cost effective drugs to minimize cost of therapy.

Feedback received from the patients and the doctors in Karachi showed that non pharmacologic recommendations were given to the patients as per the guidelines. However, gaps were identified in adherence to therapeutic guidelines by the doctors. Deviations in therapy from the guidelines were evident on different counts. For instance, diuretics were not used as recommended and expensive branded leaders were usually prescribed. Beta blockers were extensively used despite strong recommendation by different therapeutic guidelines in hypertensive patients without compelling conditions to deemphasize them because their diabetogenic potential and abstruse cardio protective role.

The perception of cost effectiveness was not clear to doctors. That’s why most of doctors considered Beta Blockers or ACEIs more cost effective than diuretic of thiazide group. Consider a patient taking a thiazide diuretic, would pay Rs. 367 only for a year-long treatment. But if other drugs were used instead of diuretics e.g. beta blockers, ACE Inhibitors, Calcium Channel Blockers or ARBs, yearly medicine cost would go up to Rs. 3,652, Rs. 3,041, Rs.6,532, Rs. 28,278 respectively for corresponding branded market leaders; Rs. 1,944, Rs. 2,452, Rs. 2,869, Rs 7,035 for generic substitutes.

### Table-V: Comparison of Annual Cost of Therapy (per Patient).

| Antihypertensive Groups | Antihypertensive Groups | Annual Cost of therapy (Rs) | Other Antihypertensive leader vs. HCTZ | Branded Market Leader vs. Generic product (Average) | Branded Market Leader vs. Generic product (Lowest price) |
|-------------------------|-------------------------|-----------------------------|----------------------------------------|-----------------------------------------------------|---------------------------------------------------------|
| **Diuretics: Thiazides**| Hydrochlorothiazide (HCTZ) | 367                         | 1                                      |                                                     |                                                         |
|                         | [Triamterene:50mg, Hydrochlorothiazide:25mg] | 1,243                       | 3                                      |                                                     |                                                         |
| **Angiotensin Converting Enzyme Inhibitors (ACEIs): Captopril**| Branded Market Leader | 3,041                       | 8                                      |                                                     |                                                         |
|                         | Generic products (Average) | 2,453                       | 7                                      | 1.2                                                 |                                                         |
|                         | Generic product (Lowest price) | 682                         | 2                                      | 4                                                   |                                                         |
| **Calcium Channel Blockers (CCBs): Amlodipine**| Branded Market Leader | 6,532                       | 18                                     |                                                     |                                                         |
|                         | Generic products (Average) | 2,869                       | 8                                      | 2.3                                                 |                                                         |
|                         | Generic product (Lowest price) | 630                         | 2                                      | 10                                                  |                                                         |
| **Beta Blockers (BBs): Atenolol**| Branded Market Leader | 3,652                       | 10                                     |                                                     |                                                         |
|                         | Generic products (Average) | 1,944                       | 5                                      | 1.9                                                 |                                                         |
|                         | Generic product (Lowest price) | 860                         | 2                                      | 4                                                   |                                                         |
| **Angiotensin Receptor Blockers (ARB): Losartan**| Branded Market Leader | 28,278                      | 77                                     |                                                     |                                                         |
|                         | Generic products (Average) | 7,035                       | 19                                     | 4.0                                                 |                                                         |
|                         | Generic product (Lowest price) | 2,984                       | 8                                      | 9                                                   |                                                         |
Feedbacks showed that therapeutic guidelines depending upon the choice of drugs. Because of choice of drugs, cost of therapy could registered by the Health Authorities in Pakistan. generic substitutes of branded market leaders 860, Rs. 682, Rs. 630, Rs. 2,984 for the lowest priced (average priced) of branded market leaders; and Rs. 600, Rs. 628, Rs. 630, Rs. 2,984 for the lowest priced
generic substitutes of branded market leaders registered by the Health Authorities in Pakistan. Because of choice of drugs, cost of therapy could increase many folds ranging from 2 to 77 times depending upon the choice of drugs.

CONCLUSION

Feedbacks showed that therapeutic guidelines were not followed for choosing pharmacologic agents by the doctors practicing in the community and hospitals in Karachi. Thiazide diuretics were hardly used. Beta blockers were widely prescribed. High priced market leaders or expensive branded generics were commonly prescribed. Therefore, great opportunities for cost minimization by used evidence-based clinically effective and safe medicines. It is concluded that national and international evidence-based therapeutic guidelines for the management of Stage I hypertension in patients without compelling indications were not followed in the selected samples of population and doctors in Karachi. The doctors have misconception about the cost effectiveness of certain antihypertensive agents. The outcomes of this study should be reflected for designing plans for patient awareness and education of health providers; and also considered for periodically updating therapeutic guidelines for blood pressure control.

Limitations of the study: Some final considerations need elaboration relating to limitations of the study. First, doctors’ viewpoints, for not complying with international therapeutic guidelines, were not explored. Secondly, patients’ opinion about the therapy they were using was also not sought. Moreover, the present work focused in Karachi region only, hence, limiting the targeting population specific to city and could not generalize the results to Pakistan as a whole.

ACKNOWLEDGEMENT

I would like to acknowledge support given to me by Dr. Naeem-uz-Zafar and Dr. Sajjad Haider of IBA, valuable suggestions given by Syeda Faiza Hassan (Center for Executive Education, IBA, Karachi) for textual change, and recommendations given by Dr. Faiza Hussain (Ziauddin University) for medical aspects. No financial support has been received for this work from any quarter.

REFERENCES

1. World Health Report of WHO 2001. http://www.who.int/whr/2001/en/
2. Jafar TH, Jessani S, Jafary FH, Ishaq M, Orkazi R, Orkazai S, et al. General Practitioners’ Approach to Hypertension in Urban Pakistan: Disturbing Trends in Practice. Circulation. 2005;111:1278-1283. doi:10.1161/01.CIR.0000157698.78949.D7.
3. Saleem F, Hassanali AA, Shafie AA. Hypertension in Pakistan: Time to Take Some Serious Action. BrJGenPract. 2010;44(9). doi:10.3399/bjgp10X302182.
4. Hameed A, Tal J, Kazmi K, Khan SA, Sultan FAT, Chandna IE, et al. The Hypertension Knowledge of General Practitioners in Karachi. Presented in the 8th Annual Symposium, Pakistan Hypertension League, Karachi, 2004 (Abstract).
5. Cohen JD. Hypertension Epidemiological Changes and Economic Burden: Redefining Risk Assessment to Lower Costs. Managed Care. 2009;51-58.
6. Arredondo A, Zuniga A. Epidemiological Changes and Financial Consequences of Hypertension in Latin America: Implications for the Health System and Patients in Mexico. Cad. SaúdePublica, Rio de Janeiro. 2012;28(3):497-502. doi:10.1590/ S0102-311X2012000300010
7. Alefan Q, Ibrahim MI, Razak TA, Ayub A. Cost of Treating Hypertension in Malaysia. Asian JPharmaceutical ClinRes. 2009;2(1):1-5.
8. Dib MW, Riera R, Ferraz MB. Estimated Annual Cost of Arterial Hypertension treatment in Brazil. Rev. PanamSaludPublica. 2010;27(2):125-131.
9. Krzysztoz ZJ, Kotigat D, Ratajczak P, Bryl W, Cymerys M, Hoffmann K, et al. Economic Aspects of Hypertension Treatment in Poland. ArchMedSci. 2013;1-11.
10. Abdulkadri AO, Cunningham-Myrie C, Forrester T. Economic Burden of Diabetes and Hypertension in Caricom States. Social & Economic Studies. 2009;58(3/4):175-197.
11. Elliot WJ. The Economic Impact of Hypertension. JClinHypert. 2003;5(3):3-13.
12. Fischer MA, Avron J. Economic Implications of Evidence based Prescribing for Hypertension. JAMA. 2004;291(51):1850-1856.
13. Pakistan Hypertension League Guidelines. Obtainable from http://www.phlpk.org/pdf/National%20Guidelines.pdf. Accessed on Feb. 02, 2015.
14. The Seventh Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment High Blood Pressure. 2004 NIH Publication No. 04-5230. Obtainable from. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed on Feb. 02, 2015.
15. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) Statement on Management of Hypertension. JHypert. 2005;21:1983–1992. doi:10.1097/01.hjh.000084751.37215.d2
16. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. Clinical Guideline 127. London: NICE; 2011. Obtained from http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf (Accessed Feb. 2, 2015)
17. Seedat YK, Rayer BL. South African Hypertension Guidelines 2011. South African MedJ. 2012;102:57-84.

Authors’ Contribution:

MIH: Conceived, designed, prepared manuscripts, Statistical analysis of data, and statistical inference.
MIH, BSN and RMQ: Data Collection. NA: Checking of References, data arrangement. BSN: Design modification, reviewed and suggested technical changes. MIH: Takes responsibility and accountable for all aspects of the work.